9.02
-1.11
(-10.96%)
Real-time:
12:11PM EDT
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | 8.91 - 9.98 |
| 52 week | 4.06 - 15.25 |
| Open | 9.59 |
| Vol / Avg. | 807,377.00/1.32M |
| Mkt cap | 977.14M |
| P/E | - |
| Div/yield | - |
| EPS | -0.35 |
| Shares | 108.33M |
| Beta | 0.49 |
| Inst. own | 61% |
Events
Jul 31, 2012
Idenix Pharmaceuticals Announces Restructuring of Development and Commercialization Collaboration With Novartis Pharma AG - Conference Call
Jul 12, 2012
Idenix Pharmaceuticals, Inc. at JMP Securities Healthcare Conference
Jun 20, 2012
Idenix Pharmaceuticals, Inc. at Wells Fargo Health Care Conference
Jun 7, 2012
Idenix Pharmaceuticals, Inc. Annual Shareholder Meeting
May 15, 2012
Idenix Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
May 7, 2012
Idenix Pharmaceuticals, Inc. at Deutsche Bank AG Health Care Conference -
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '12) | 2011 | |
| Net profit margin | 32.12% | -747.79% |
| Operating margin | 31.16% | -768.35% |
| EBITD margin | - | -707.94% |
| Return on average assets | 34.25% | -49.29% |
| Return on average equity | 75.15% | -516.46% |
| Employees | 105 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Idenix Pharmaceuticals, Inc. (Idenix) is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company�s research and development focus is on the treatment of hepatitis C virus (HCV). In July 2011, it initiated a phase IIb clinical trial of IDX184 in combination with pegylated interferon and ribavirin (Peg-IFN/RBV), in treatment- HCV genotype 1-infected patients. Its drug candidate for its NS5A inhibitor program is IDX719. In December 2011, it filed an investigational new drug application (IND) for IDX719 and in January 2012, it initiated a phase I clinical study.
Officers and directors
| Thomas R. Hodgson | Independent Chairman of the Board | |
| Ronald C. Renaud Jr. | President, Chief Executive Officer, Director | |
| Daniella Beckman | Chief Financial Officer, Senior Vice President, Treasurer | |
| David N. Standring Ph.D. | Executive Vice President, Chief Scientific Officer | |
| Douglas Mayers M.D. | Executive Vice President - Clinical Development, Chief Medical Officer | |
| Maria D. Stahl | Senior Vice President, General Counsel, Secretary | |
| Paul J. Fanning | Senior Vice President - Human Resources | |
| Robert E. Pelzer | Director | |
| Wayne T. Hockmeyer Ph.D. | Independent Director | |
| Tamar D. Howson | Independent Director |